Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
68.2 USD | -2.80% | -8.17% | +9.28% |
Financials (USD)
Sales 2024 * | 114M | Sales 2025 * | 404M | Capitalization | 5.63B |
---|---|---|---|---|---|
Net income 2024 * | -454M | Net income 2025 * | -381M | EV / Sales 2024 * | 35.9 x |
Net cash position 2024 * | 1.55B | Net cash position 2025 * | 1.39B | EV / Sales 2025 * | 10.5 x |
P/E ratio 2024 * |
-12.8
x | P/E ratio 2025 * |
-16.5
x | Employees | 407 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.37% |
Latest transcript on CRISPR Therapeutics AG
1 day | -1.14% | ||
1 week | -3.81% | ||
Current month | -16.69% | ||
1 month | -21.27% | ||
3 months | +8.00% | ||
6 months | +48.86% | ||
Current year | +12.08% |
Managers | Title | Age | Since |
---|---|---|---|
Samarth Kulkarni
CEO | Chief Executive Officer | 45 | 15-07-31 |
Raju Prasad
DFI | Director of Finance/CFO | 40 | 23-03-13 |
Stephen Kennedy
CTO | Chief Tech/Sci/R&D Officer | 67 | 19-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Doug Treco Treco
BRD | Director/Board Member | 66 | 20-06-10 |
Simeon George
BRD | Director/Board Member | 46 | 15-04-28 |
Ali Behbahani
BRD | Director/Board Member | 47 | 15-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
10.82% | 227 M€ | +6.90% | - | |
8.55% | 2 M€ | -25.75% | ||
4.84% | 1 M€ | 0.00% | - | |
4.53% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 68.4 | -2.51% | 1 166 732 |
24-03-27 | 70.16 | -1.14% | 1,340,687 |
24-03-26 | 70.97 | -0.15% | 835,997 |
24-03-25 | 71.08 | -0.74% | 909,468 |
24-03-22 | 71.61 | -3.88% | 1,024,384 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.08% | 5.63B | |
+9.16% | 45.97B | |
+53.29% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |